STOCK TITAN

[SCHEDULE 13G/A] Vaxcyte, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Janus Henderson Group plc filed a Schedule 13G/A reporting a sizable stake in Vaxcyte, Inc. The filing discloses an aggregate beneficial ownership reported as 14,691,344 shares (11.4% of the class). The document also states that an indirect subsidiary, JHIUS, may be deemed to beneficially own 14,554,724 shares (11.3% of the class), and that shared voting and shared dispositive power apply to those subsidiary-held shares.

The filing includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control, and it attaches a power of attorney authorizing two officers to make future ownership filings on the company’s behalf.

Janus Henderson Group plc ha depositato un Schedule 13G/A segnalando una partecipazione rilevante in Vaxcyte, Inc.. Il deposito indica una proprietà beneficiaria complessiva di 14.691.344 azioni (11,4% della classe). Il documento precisa inoltre che una controllata indiretta, JHIUS, può essere considerata beneficiaria di 14.554.724 azioni (11,3% della classe) e che su tali azioni detenute dalla controllata si applicano diritti di voto condivisi e poteri dispositivi condivisi.

Il deposito contiene inoltre una certificazione che i titoli sono detenuti nell'ordinario corso dell'attività e non allo scopo di modificare o influenzare il controllo, e allega una procura che autorizza due dirigenti a effettuare future comunicazioni di partecipazione per conto della società.

Janus Henderson Group plc presentó un Schedule 13G/A que informa de una participación significativa en Vaxcyte, Inc.. La presentación declara una propiedad beneficiosa agregada de 14.691.344 acciones (11,4% de la clase). El documento también indica que una subsidiaria indirecta, JHIUS, puede considerarse beneficiaria de 14.554.724 acciones (11,3% de la clase), y que dichas acciones en manos de la subsidiaria están sujetas a voto compartido y a poder dispositvo compartido.

La presentación incluye una certificación de que los valores se mantienen en el curso ordinario del negocio y no con el objetivo de cambiar o influir en el control, y adjunta un poder notarial que autoriza a dos ejecutivos a presentar futuras comunicaciones de propiedad en nombre de la empresa.

Janus Henderson Group plcVaxcyte, Inc.에 대한 상당한 지분을 보고하는 Schedule 13G/A를 제출했습니다. 제출서에는 총 실질 소유가 14,691,344주(총주식의 11.4%)로 보고되어 있습니다. 문서에는 또한 간접 자회사인 JHIUS가 14,554,724주(총주식의 11.3%)를 실질적으로 보유한 것으로 간주될 수 있으며, 해당 자회사 보유 주식에는 공동 의결권과 공동 처분권이 적용된다고 명시되어 있습니다.

제출서에는 또한 해당 증권이 영업의 통상적 범위 내에서 보유되고 있으며 지배권을 변경하거나 영향력을 행사할 목적이 아님을 인증하는 문서가 포함되어 있고, 두 명의 임원이 향후 회사 명의로 소유 관련 서류를 제출하도록 권한을 부여하는 위임장이 첨부되어 있습니다.

Janus Henderson Group plc a déposé un Schedule 13G/A signalant une participation importante dans Vaxcyte, Inc.. Le document déclare une propriété bénéficiaire totale de 14 691 344 actions (11,4 % de la catégorie). Il précise également qu'une filiale indirecte, JHIUS, peut être considérée comme bénéficiaire de 14 554 724 actions (11,3 % de la catégorie), et que ces actions détenues par la filiale sont soumises à des droits de vote partagés et à un pouvoir de disposition partagé.

Le dossier comprend en outre une certification indiquant que les titres sont détenus dans le cours normal des activités et non dans le but de modifier ou d'influencer le contrôle, et il joint une procuration autorisant deux dirigeants à effectuer, au nom de la société, les dépôts futurs relatifs à la détention.

Janus Henderson Group plc hat ein Schedule 13G/A eingereicht, in dem eine erhebliche Beteiligung an Vaxcyte, Inc. gemeldet wird. Die Einreichung weist eine gesamte wirtschaftliche Eigentümerschaft von 14.691.344 Aktien (11,4 % der Klasse) aus. Das Dokument besagt außerdem, dass eine indirekte Tochtergesellschaft, JHIUS, als wirtschaftliche Eigentümerin von 14.554.724 Aktien (11,3 % der Klasse) angesehen werden kann und dass für diese von der Tochter gehaltenen Aktien gemeinsame Stimmrechte und gemeinsames Verfügungsrecht gelten.

Die Einreichung enthält ferner eine Bestätigung, dass die Wertpapiere im gewöhnlichen Geschäftsverkehr gehalten werden und nicht zum Zweck der Änderung oder Beeinflussung der Kontrolle, sowie eine Vollmacht, die zwei Mitarbeitern die Befugnis erteilt, künftige Meldepflichten zur Beteiligung im Namen der Gesellschaft wahrzunehmen.

Positive
  • Material institutional stake reported: Janus Henderson Group plc is reported to beneficially own 14,691,344 shares (11.4%) of Vaxcyte common stock.
  • Subsidiary holdings disclosed: An indirect subsidiary, JHIUS, is identified as possibly beneficially owning 14,554,724 shares (11.3%), with shared voting and dispositive power.
  • Compliance and delegation: The filing includes a power of attorney authorizing designated officers to make and amend required ownership filings.
Negative
  • Inconsistent reported figures: The document presents two slightly different aggregates (14,691,344 versus 14,554,724) which are both stated in the filing and may require clarification.

Insights

TL;DR: Institutional stake above 10% is material disclosure but appears to be a passive holding per the filer.

The reported ownership level exceeds typical 5% reporting thresholds and is therefore material to shareholders and analysts monitoring ownership concentration. The filing shows shared voting and dispositive power over roughly 14.5 million shares, representing about 11% of the outstanding class, which is large enough to matter for block votes or shareholder engagement. The submission also contains a certification that the position is held in the ordinary course of business, indicating no stated intent to seek control. Investors should note the explicit figures reported and treat this as a routine institutional disclosure of a meaningful passive stake.

TL;DR: Filing documents significant passive ownership and includes governance-related filings but shows minor internal reporting inconsistencies.

The schedule includes a power of attorney delegating authority to two officers to file future reports, which centralizes compliance for ownership disclosures. The filer affirms the holdings are not intended to change control. The document contains two closely related ownership figures for the reporting entity and an indirect subsidiary, which are explicitly presented in the filing and may warrant internal reconciliation or an explanatory exhibit to avoid investor confusion. Overall, this is a material, procedurally standard disclosure for a large institutional holder.

Janus Henderson Group plc ha depositato un Schedule 13G/A segnalando una partecipazione rilevante in Vaxcyte, Inc.. Il deposito indica una proprietà beneficiaria complessiva di 14.691.344 azioni (11,4% della classe). Il documento precisa inoltre che una controllata indiretta, JHIUS, può essere considerata beneficiaria di 14.554.724 azioni (11,3% della classe) e che su tali azioni detenute dalla controllata si applicano diritti di voto condivisi e poteri dispositivi condivisi.

Il deposito contiene inoltre una certificazione che i titoli sono detenuti nell'ordinario corso dell'attività e non allo scopo di modificare o influenzare il controllo, e allega una procura che autorizza due dirigenti a effettuare future comunicazioni di partecipazione per conto della società.

Janus Henderson Group plc presentó un Schedule 13G/A que informa de una participación significativa en Vaxcyte, Inc.. La presentación declara una propiedad beneficiosa agregada de 14.691.344 acciones (11,4% de la clase). El documento también indica que una subsidiaria indirecta, JHIUS, puede considerarse beneficiaria de 14.554.724 acciones (11,3% de la clase), y que dichas acciones en manos de la subsidiaria están sujetas a voto compartido y a poder dispositvo compartido.

La presentación incluye una certificación de que los valores se mantienen en el curso ordinario del negocio y no con el objetivo de cambiar o influir en el control, y adjunta un poder notarial que autoriza a dos ejecutivos a presentar futuras comunicaciones de propiedad en nombre de la empresa.

Janus Henderson Group plcVaxcyte, Inc.에 대한 상당한 지분을 보고하는 Schedule 13G/A를 제출했습니다. 제출서에는 총 실질 소유가 14,691,344주(총주식의 11.4%)로 보고되어 있습니다. 문서에는 또한 간접 자회사인 JHIUS가 14,554,724주(총주식의 11.3%)를 실질적으로 보유한 것으로 간주될 수 있으며, 해당 자회사 보유 주식에는 공동 의결권과 공동 처분권이 적용된다고 명시되어 있습니다.

제출서에는 또한 해당 증권이 영업의 통상적 범위 내에서 보유되고 있으며 지배권을 변경하거나 영향력을 행사할 목적이 아님을 인증하는 문서가 포함되어 있고, 두 명의 임원이 향후 회사 명의로 소유 관련 서류를 제출하도록 권한을 부여하는 위임장이 첨부되어 있습니다.

Janus Henderson Group plc a déposé un Schedule 13G/A signalant une participation importante dans Vaxcyte, Inc.. Le document déclare une propriété bénéficiaire totale de 14 691 344 actions (11,4 % de la catégorie). Il précise également qu'une filiale indirecte, JHIUS, peut être considérée comme bénéficiaire de 14 554 724 actions (11,3 % de la catégorie), et que ces actions détenues par la filiale sont soumises à des droits de vote partagés et à un pouvoir de disposition partagé.

Le dossier comprend en outre une certification indiquant que les titres sont détenus dans le cours normal des activités et non dans le but de modifier ou d'influencer le contrôle, et il joint une procuration autorisant deux dirigeants à effectuer, au nom de la société, les dépôts futurs relatifs à la détention.

Janus Henderson Group plc hat ein Schedule 13G/A eingereicht, in dem eine erhebliche Beteiligung an Vaxcyte, Inc. gemeldet wird. Die Einreichung weist eine gesamte wirtschaftliche Eigentümerschaft von 14.691.344 Aktien (11,4 % der Klasse) aus. Das Dokument besagt außerdem, dass eine indirekte Tochtergesellschaft, JHIUS, als wirtschaftliche Eigentümerin von 14.554.724 Aktien (11,3 % der Klasse) angesehen werden kann und dass für diese von der Tochter gehaltenen Aktien gemeinsame Stimmrechte und gemeinsames Verfügungsrecht gelten.

Die Einreichung enthält ferner eine Bestätigung, dass die Wertpapiere im gewöhnlichen Geschäftsverkehr gehalten werden und nicht zum Zweck der Änderung oder Beeinflussung der Kontrolle, sowie eine Vollmacht, die zwei Mitarbeitern die Befugnis erteilt, künftige Meldepflichten zur Beteiligung im Namen der Gesellschaft wahrzunehmen.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



JANUS HENDERSON GROUP PLC
Signature:Kristin Mariani
Name/Title:Head of North America Compliance, CCO
Date:08/14/2025
Exhibit Information

POWER OF ATTORNEY The undersigned, Janus Henderson Group plc ("the Company"), does hereby make, constitute and appoint each of Kristin Mariani and Caroline Barotti acting severally, as its true and lawful attorneys in-fact, for the purpose of, from time to time, executing in its name and on its behalf, whether the Company individually or as representative of others, any and all documents, certificates, instruments, statements, other filings and amendments to the foregoing (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Forms 13D, 13F, 13G and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental, regulatory authority or other person, and giving and granting to each such attorney-in-fact power and authority to act in the premises as fully and to all intents and purposes as the Company might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 9th day of December, 2022. Janus Henderson Group plc By: /s/ Michelle Rosenberg Name: Michelle Rosenberg Title: General Counsel and Company Secretary

FAQ

How many Vaxcyte (PCVX) shares does Janus Henderson report owning?

The filing reports an aggregate beneficial ownership of 14,691,344 shares for Janus Henderson Group plc and notes an indirect subsidiary may beneficially own 14,554,724 shares.

What percentage of Vaxcyte (PCVX) does Janus Henderson's stake represent?

The filing shows the stake represents about 11.4% of the class for the reporting person and 11.3% for the referenced subsidiary.

Does Janus Henderson have voting or dispositive power over the reported shares?

Yes. The filing states shared voting power and shared dispositive power over the reported subsidiary-held shares.

Is the stake held to change or influence control of Vaxcyte (PCVX)?

The filing includes a certification that the securities are held in the ordinary course of business and were not acquired or held for the purpose of changing or influencing control.

Who signed the Schedule 13G/A for Janus Henderson Group plc?

The filing is signed by Kristin Mariani, Head of North America Compliance, CCO, on behalf of Janus Henderson Group plc.
Vaxcyte, Inc.

NASDAQ:PCVX

PCVX Rankings

PCVX Latest News

PCVX Latest SEC Filings

PCVX Stock Data

3.89B
127.68M
0.68%
117.56%
10.56%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SAN CARLOS